PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
41.18%
R&D growth above 1.5x TRVN's 2.10%. Michael Burry would check for spending discipline.
22.12%
G&A change of 22.12% while TRVN maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.03%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
35.03%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
14.84%
D&A growth above 1.5x TRVN's 2.80%. Michael Burry would check for excessive investment.
-35.35%
EBITDA decline while TRVN shows 38.77% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Operating income decline while TRVN shows 38.77% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-15.72%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-37.55%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.55%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-34.88%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-34.88%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
2.03%
Share count reduction exceeding 1.5x TRVN's 20.70%. David Dodd would verify capital allocation.
2.03%
Diluted share reduction exceeding 1.5x TRVN's 20.70%. David Dodd would verify capital allocation.